Details of the Drug
General Information of Drug (ID: DM2SNR0)
| Drug Name |
1-(3-Fluoro-phenyl)-piperazine
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
1-(3-Fluorophenyl)piperazine; 3801-89-6; 1-(3-Fluoro-phenyl)-piperazine; Piperazine, 1-(3-fluorophenyl)-; 1-(3-fluorophenyl)-piperazine; CHEMBL269784; Piperazine,1-(3-fluorophenyl)-; EINECS 223-271-9; AC1Q4NBT; 3-fluorophenyl piperazine; (3-fluorophenyl)piperazine; AC1L2T0A; 4-(3-fluorophenyl)piperazine; N-(3-Fluorophenyl)piperazine; SCHEMBL315894; CTK4H9144; DTXSID40191426; MolPort-000-155-895; KIFCSMQTGWVMOD-UHFFFAOYSA-N; ZINC2529848; SBB089693; ANW-61692; 4877AB; BDBM50017455; AKOS000101159; FS-1513; KB-85106; AS-10296
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 180.22 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.2 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


